Understanding Myocardial Metabolism in the Context of Cardio-Oncology.

Abstract

Cardiovascular events, ranging from arrhythmias to decompensated heart failure, are common during and after cancer therapy. Cardiovascular complications can be life-threatening, and from the oncologist's perspective, could limit the use of first-line cancer therapeutics. Moreover, an aging population increases the risk for comorbidities and medical complexity among patients who undergo cancer therapy. Many have established cardiovascular diagnoses or risk factors before starting these therapies. Therefore, it is essential to understand the molecular mechanisms that drive cardiovascular events in patients with cancer and to identify new therapeutic targets that may prevent and treat these 2 diseases. This review will discuss the metabolic interaction between cancer and the heart and will highlight current strategies of targeting metabolic pathways for cancer treatment. Finally, this review highlights opportunities and challenges in advancing our understanding of myocardial metabolism in the context of cancer and cancer treatment.

• Authors: Jing Liu, Zsu-Zsu Chen, Jagvi Patel, Aarti Asnani
• Journal: Heart failure clinics (Heart Fail Clin) Vol. 18 Issue 3 Pg. 415-424 (Jul 2022) ISSN: 1551-7136 [Print] United States
• PMID: 35718416 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2022 Elsevier Inc. All rights reserved.

Chemical References

• Antineoplastic Agents

Topics

• Aged
• Antineoplastic Agents (adverse effects)
• Cardiotoxicity (prevention & control)
• Cardiovascular Diseases (diagnosis, etiology)
• Heart
• Heart Diseases
• Humans
• Medical Oncology
• Neoplasms (drug therapy, therapy)